CeriBell (CBLL) is back in focus after the U.S. Food and Drug Administration cleared new software for its Ceribell System, expanding bedside EEG tools for both neonatal and adult critical care settings.
The clearance landed on a stock that has already been gaining attention, with CeriBell’s share price returning 3.48% over the last day, 10.62% over 30 days and 34.74% across 90 days. Total shareholder return over the past year sits at 109.79%, indicating strong recent momentum that this FDA news is likely reinforcing.
Scan beyond CeriBell and see how other healthcare AI stocks are reacting to similar catalysts with our curated list of 33 healthcare AI stocks.
CeriBell has already delivered a sharp run on the back of FDA clearance and rapid top line expansion, so the real tension now is simple: Is most of the upside already in the rearview, or is valuation still leaving meaningful headroom?
Preferred Price-to-Sales Multiple of 9.8x: Is It Justified?
CeriBell’s recent rally now lines up with a rich valuation profile. The stock trades on a P/S ratio of 9.8x, while analysts’ average price target of $28.57 sits only about 9.3% above the last close at $26.14.
The P/S multiple compares the company’s market value to its annual revenue, which is $102 million for CeriBell. For a medical technology business that remains loss making, investors often lean on sales-based measures because earnings are still negative and forecasts point to continued losses over the next three years.
Revenue is forecast to grow 20.8% per year, compared with the wider US market at 13.7%. That growth outlook can explain why buyers are paying more per dollar of sales. Even so, CeriBell’s current P/S of 9.8x is described as expensive against both the peer average of 3.6x and the broader US Medical Equipment industry at 2.5x. It is also high relative to an estimated fair P/S ratio of 7.2x, a level the market could potentially move toward if enthusiasm fades or growth expectations are reassessed.
That comparison to an estimated fair ratio is important because it frames how much optimism is already embedded in the share price. With the stock also flagged as unprofitable, posting a return on equity of 51.43% in the red and carrying higher risk funding sources, the high P/S figure asks investors to accept execution and financing risks while paying a premium to sector averages.
Explore the SWS fair ratio for CeriBell.
Result: Price-to-sales of 9.8x (OVERVALUED)
Still, CeriBell’s reliance on a single product platform and ongoing net loss of $65.997 million could quickly challenge sentiment if revenue momentum stumbles.
Find out about the key risks to this CeriBell narrative.
Next Steps
Mixed signals on CeriBell so far. If you want to move quickly and build your own view from the ground up, start by weighing its 1 key reward and 2 important warning signs.
Looking for more CeriBell-sized opportunities?
Do not stop with CeriBell. Broaden your watchlist with fresh ideas now, or risk missing companies that better match your risk, income, and value goals.
- Target potential mispricings by scanning for quality businesses trading on compelling valuations through our 32 high quality undervalued stocks.
- Strengthen your income stream by filtering for companies built around resilient cash payouts using the 8 dividend fortresses.
- Prioritise resilience first and hunt for steadier performers with the 32 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com